Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance.

[1]  Aasld Idsa Hcv Guidance Panel.  Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus , 2015, Hepatology.

[2]  T. O'Brien,et al.  Reply: Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C , 2015, Open forum infectious diseases.

[3]  Z. Kutalik,et al.  Correction: Corrigendum: Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes , 2014, Nature Communications.

[4]  T. O'Brien,et al.  Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C , 2014, Open forum infectious diseases.

[5]  L. Prokunina-Olsson,et al.  IFN-λ4: the paradoxical new member of the interferon lambda family. , 2014, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[6]  Z. Kutalik,et al.  75: A variant of IFNλ4 displaying decreased activity is associated with better hepatitis C virus clearance and reduced ISG expression , 2014 .

[7]  M. Dennis,et al.  Selection on a Variant Associated with Improved Viral Clearance Drives Local, Adaptive Pseudogenization of Interferon Lambda 4 (IFNL4) , 2014, PLoS genetics.

[8]  L. Prokunina-Olsson,et al.  Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. , 2014, The Journal of clinical investigation.

[9]  L. Prokunina-Olsson,et al.  IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. , 2014, The Journal of infectious diseases.

[10]  Robert Herring,et al.  Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. , 2014, The New England journal of medicine.

[11]  J. Hoofnagle,et al.  Therapy for hepatitis C--the costs of success. , 2014, The New England journal of medicine.

[12]  E. Galmozzi,et al.  Nonsynonymous variant Pro70Ser (rs117648444) in IFNL4 gene identifies carriers of the rs368234815 ΔG allele with higher HCV RNA decline during the first 4 weeks of pegylated interferon and ribavirin therapy in HCV-1 patients. , 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[13]  P. Ferenci,et al.  Review article: genetic factors that modify the outcome of viral hepatitis , 2014, Alimentary pharmacology & therapeutics.

[14]  L. Prokunina-Olsson,et al.  Association of the IFNL4-ΔG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus. , 2014, The Journal of infectious diseases.

[15]  B. Clotet,et al.  IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients , 2014, AIDS.

[16]  M. Carrington,et al.  The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus–induced microRNAs , 2013, Nature Immunology.

[17]  T. Pietschmann,et al.  Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses , 2013, The EMBO journal.

[18]  M. Buti,et al.  Faldaprevir and deleobuvir for HCV genotype 1 infection. , 2013, The New England journal of medicine.

[19]  F. Negro,et al.  IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction , 2013, The Journal of experimental medicine.

[20]  Barbara Rehermann,et al.  A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus , 2013, Nature Genetics.

[21]  Pål Sætrom,et al.  Single Nucleotide Polymorphisms Can Create Alternative Polyadenylation Signals and Affect Gene Expression through Loss of MicroRNA-Regulation , 2012, PLoS Comput. Biol..

[22]  M. Abdel-hamid,et al.  Analysis of IL28B Variants in an Egyptian Population Defines the 20 Kilobases Minimal Region Involved in Spontaneous Clearance of Hepatitis C Virus , 2012, PloS one.

[23]  B. Clotet,et al.  Deciphering the Interleukin 28B Variants That Better Predict Response to Pegylated Interferon-α and Ribavirin Therapy in HCV/HIV-1 Coinfected Patients , 2012, PloS one.

[24]  J. Casanova,et al.  Evolutionary genetic dissection of human interferons , 2011, The Journal of experimental medicine.

[25]  F. Pereyra,et al.  Differential microRNA regulation of HLA-C expression and its association with HIV control , 2011, Nature.

[26]  Sven Bergmann,et al.  Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. , 2010, Gastroenterology.

[27]  David B. Goldstein,et al.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus , 2009, Nature.

[28]  A. Koike,et al.  Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.

[29]  Thomas Berg,et al.  IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy , 2009, Nature Genetics.

[30]  Jacques Fellay,et al.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.

[31]  J. Hoofnagle,et al.  Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection. , 2009, The Journal of infectious diseases.

[32]  B. A. Fox,et al.  The Role of Genomic Data in the Discovery, Annotation and Evolutionary Interpretation of the Interferon-Lambda Family , 2009, PloS one.

[33]  T. O'Brien,et al.  Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000 , 2007, Hepatology.

[34]  H. Conjeevaram,et al.  Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. , 2006, Gastroenterology.

[35]  M. Young,et al.  The Women's Interagency HIV Study: an Observational Cohort Brings Clinical Sciences to the Bench , 2005, Clinical Diagnostic Laboratory Immunology.

[36]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[37]  William M. Lee,et al.  Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. , 2004, Controlled clinical trials.

[38]  M. Pepe.  The Statistical Evaluation of Medical Tests for Classification and Prediction , 2003 .

[39]  J. Watters,et al.  HIV seroprevalence in injection drug users. , 1995, JAMA.

[40]  A Munoz,et al.  The Alive Study: A Longitudinal Study of HIV-1 Infection in Intravenous Drug Users: Description of Methods , 1991, NIDA research monograph.

[41]  D. Harnois.  Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon , 2009 .

[42]  A. Lewis-Antes,et al.  IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. , 2003, Nature immunology.

[43]  Scott R. Presnell,et al.  IL-28, IL-29 and their class II cytokine receptor IL-28R , 2002, Nature Immunology.